In addition to Namisol®, Echo Pharmaceuticals is developing a dosage form with Cannabidiol (CBD). CBD is a potential drug candidate for numerous indications, of which Schizophrenia in particular is one.
We are continuously exploring new areas of development in order to define potential new applications of cannabinoids and increase our portfolio by creating other nascent cannabinoid-based medicines. This is reflected in our pharmaceutical pipeline.
Please click one of the indications for additional information: